Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review

Orkun Tan, Karen Bradshaw, Bruce R. Carr

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

OBJECTIVE: Menopause and its transition represent significant risk factors for the development of vulvovaginal atrophy-related sexual dysfunction. The objective of this study was to review the hormonal and nonhormonal therapies available for postmenopausal women with vulvovaginal atrophy-related sexual dysfunction, focusing on practical recommendations through a literature review of the most relevant publications in this field. METHODS: This study is a literature review. RESULTS: Available vaginal estrogen preparations are conjugated equine estrogens, estradiol vaginal cream, a sustained-release intravaginal estradiol ring, or a low-dose estradiol tablet. Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy. Vaginal lubricants and moisturizers applied on a regular basis have an efficacy comparable with that of local estrogen therapy and should be offered to women wishing to avoid the use of vaginal estrogens. CONCLUSIONS: Oral, transdermal, or vaginal estrogen preparations are the most effective treatment options for vulvovaginal atrophy-related sexual dysfunction. Selective estrogen receptor modulators such as lasofoxifene and ospemifene showed a positive impact on vaginal tissue in postmenopausal women. Vaginal dehydroepiandrostenedione, vaginal testosterone, and tissue selective estrogen complexes are also emerging as promising new therapies; however, further studies are warranted to confirm their efficacy and safety.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalMenopause
Volume19
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Atrophy
Estrogens
Estradiol
Foams and Jellies Vaginal Creams
Selective Estrogen Receptor Modulators
Conjugated (USP) Estrogens
Lubricants
Therapeutics
Menopause
Tablets
Testosterone
Publications
Breast Neoplasms
Safety

Keywords

  • Dehydroepiandrosterone
  • Estrogens
  • Menopause
  • Selective estrogen receptor modulators
  • Sexual dysfunction
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women : An up-to-date review. / Tan, Orkun; Bradshaw, Karen; Carr, Bruce R.

In: Menopause, Vol. 19, No. 1, 01.2012, p. 109-117.

Research output: Contribution to journalArticle

@article{72e8820164544faab7802b68a470bdb9,
title = "Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: An up-to-date review",
abstract = "OBJECTIVE: Menopause and its transition represent significant risk factors for the development of vulvovaginal atrophy-related sexual dysfunction. The objective of this study was to review the hormonal and nonhormonal therapies available for postmenopausal women with vulvovaginal atrophy-related sexual dysfunction, focusing on practical recommendations through a literature review of the most relevant publications in this field. METHODS: This study is a literature review. RESULTS: Available vaginal estrogen preparations are conjugated equine estrogens, estradiol vaginal cream, a sustained-release intravaginal estradiol ring, or a low-dose estradiol tablet. Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy. Vaginal lubricants and moisturizers applied on a regular basis have an efficacy comparable with that of local estrogen therapy and should be offered to women wishing to avoid the use of vaginal estrogens. CONCLUSIONS: Oral, transdermal, or vaginal estrogen preparations are the most effective treatment options for vulvovaginal atrophy-related sexual dysfunction. Selective estrogen receptor modulators such as lasofoxifene and ospemifene showed a positive impact on vaginal tissue in postmenopausal women. Vaginal dehydroepiandrostenedione, vaginal testosterone, and tissue selective estrogen complexes are also emerging as promising new therapies; however, further studies are warranted to confirm their efficacy and safety.",
keywords = "Dehydroepiandrosterone, Estrogens, Menopause, Selective estrogen receptor modulators, Sexual dysfunction, Vulvovaginal atrophy",
author = "Orkun Tan and Karen Bradshaw and Carr, {Bruce R.}",
year = "2012",
month = "1",
doi = "10.1097/gme.0b013e31821f92df",
language = "English (US)",
volume = "19",
pages = "109--117",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women

T2 - An up-to-date review

AU - Tan, Orkun

AU - Bradshaw, Karen

AU - Carr, Bruce R.

PY - 2012/1

Y1 - 2012/1

N2 - OBJECTIVE: Menopause and its transition represent significant risk factors for the development of vulvovaginal atrophy-related sexual dysfunction. The objective of this study was to review the hormonal and nonhormonal therapies available for postmenopausal women with vulvovaginal atrophy-related sexual dysfunction, focusing on practical recommendations through a literature review of the most relevant publications in this field. METHODS: This study is a literature review. RESULTS: Available vaginal estrogen preparations are conjugated equine estrogens, estradiol vaginal cream, a sustained-release intravaginal estradiol ring, or a low-dose estradiol tablet. Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy. Vaginal lubricants and moisturizers applied on a regular basis have an efficacy comparable with that of local estrogen therapy and should be offered to women wishing to avoid the use of vaginal estrogens. CONCLUSIONS: Oral, transdermal, or vaginal estrogen preparations are the most effective treatment options for vulvovaginal atrophy-related sexual dysfunction. Selective estrogen receptor modulators such as lasofoxifene and ospemifene showed a positive impact on vaginal tissue in postmenopausal women. Vaginal dehydroepiandrostenedione, vaginal testosterone, and tissue selective estrogen complexes are also emerging as promising new therapies; however, further studies are warranted to confirm their efficacy and safety.

AB - OBJECTIVE: Menopause and its transition represent significant risk factors for the development of vulvovaginal atrophy-related sexual dysfunction. The objective of this study was to review the hormonal and nonhormonal therapies available for postmenopausal women with vulvovaginal atrophy-related sexual dysfunction, focusing on practical recommendations through a literature review of the most relevant publications in this field. METHODS: This study is a literature review. RESULTS: Available vaginal estrogen preparations are conjugated equine estrogens, estradiol vaginal cream, a sustained-release intravaginal estradiol ring, or a low-dose estradiol tablet. Vaginal estrogen preparations with the lowest systemic absorption rate may be preferred in women with history of breast cancer and severe vaginal atrophy. Vaginal lubricants and moisturizers applied on a regular basis have an efficacy comparable with that of local estrogen therapy and should be offered to women wishing to avoid the use of vaginal estrogens. CONCLUSIONS: Oral, transdermal, or vaginal estrogen preparations are the most effective treatment options for vulvovaginal atrophy-related sexual dysfunction. Selective estrogen receptor modulators such as lasofoxifene and ospemifene showed a positive impact on vaginal tissue in postmenopausal women. Vaginal dehydroepiandrostenedione, vaginal testosterone, and tissue selective estrogen complexes are also emerging as promising new therapies; however, further studies are warranted to confirm their efficacy and safety.

KW - Dehydroepiandrosterone

KW - Estrogens

KW - Menopause

KW - Selective estrogen receptor modulators

KW - Sexual dysfunction

KW - Vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=84655162729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84655162729&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e31821f92df

DO - 10.1097/gme.0b013e31821f92df

M3 - Article

C2 - 22011753

AN - SCOPUS:84655162729

VL - 19

SP - 109

EP - 117

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -